SEC Comment Letter for PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075) (PMCB) — Sep 10, 2004
PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075)
Date: Sept. 10, 2004 · CIK: 0001157075 · Accession: 0000000000-04-029160
AI Filing Summary & Sentiment
File numbers found in text: 333-118446, 333-68008
Show Raw Text
<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
September 9, 2004
via U.S. Mail via facsimile
Mr. Clarence W. Karney Mr. Ryan Hong, Esq.
Chief Executive Officer Richardson & Patel LLP
eFoodSafety.com, Inc. (310) 208-1154
1370 St. George Circle
Prescott, Arizona 86301
Re: eFoodSafety.com, Inc.
Form SB-2 filed August 20, 2004
File No. 333-118446
Form 10-KSB for the period ending April 30, 2004
Filed August 13, 2004
File No. 333-68008
Forms 10-QSB filed August 26, 2003, December 15, 2003 and
March 15, 2004
Dear Mr. Karney:
We have limited our review of your Form SB-2 and periodic reports and
have the following limited comments. Where indicated, we think you
should revise your document in response to these comments. If you
disagree, we will consider your explanation as to why our comment is
inapplicable or a revision is unnecessary. Please be as detailed as
necessary in your explanation. In some of our comments, we may ask
you to provide us with supplemental information so we may better
understand your disclosure. After reviewing this information, we may
or may not raise additional comments.
Please understand that the purpose of our review process is to
assist you in your compliance with the applicable disclosure
requirements and to enhance the overall disclosure in your filing.
We look forward to working with you in these respects. We welcome
any questions you may have about our comments or on any other aspect
of our review. Feel free to call us at the telephone numbers listed
at the end of this letter.
Form 10-KSB for the fiscal year ended April 30, 2004
Item 14. Controls and Procedures, page 18
1. The second full paragraph of this section indicates that "[t]here
have been no significant changes in the Company`s internal controls
or in other factors since the date of the Chief Executive Officer`s
and Chief Financial Officer`s evaluation that could significantly
affect these internal controls, including any corrective actions with
regards to significant deficiencies and material weaknesses." Revise
this disclosure to comply with Item 308(c) of Regulation S-K.
Specifically, provide disclosure as to whether there have been "any
changes," as opposed to "significant changes." Consult the last
paragraph of section II.J. found in Release No. 33-8238 for
additional guidance. Revise this language in the Forms 10-QSB cited
above.
Closing Comments
Please amend the above filing in response to these comments.
You may wish to provide us with marked copies of the amendment to
expedite our review. Please furnish a cover letter with your
amendment that keys your responses to our comments and provides any
requested supplemental information. Detailed cover letters greatly
facilitate our review. Please file your cover letter on EDGAR.
Please understand that we may have additional comments after
reviewing your amendment and responses to our comments.
We urge all persons who are responsible for the accuracy and
adequacy of the disclosure in the filings reviewed by the staff to be
certain that they have provided all information investors require for
an informed decision. Since the company and its management are in
possession of all facts relating to a company`s disclosure, they are
responsible for the accuracy and adequacy of the disclosures they
have made.
Notwithstanding our comments, in the event you request
acceleration of the effective date of the pending registration
statement, you should furnish a letter, at the time of such request,
acknowledging that
? should the Commission or the staff, acting pursuant to delegated
authority, declare the filing effective, it does not foreclose the
Commission from taking any action with respect to the filing;
? the action of the Commission or the staff, acting pursuant to
delegated authority, in declaring the filing effective, does not
relieve the company from its full responsibility for the adequacy and
accuracy of the disclosure in the filing; and
? the company may not assert this action as defense in any
proceeding initiated by the Commission or any person under the
federal securities laws of the United States.
In addition, please be advised that the Division of Enforcement
has access to all information you provide to the staff of the
Division of Corporation Finance in connection with our review of your
filing or in response to our comments on your filing.
We will consider a written request for acceleration of the effective
date of the registration statement as a confirmation of the fact that
those requesting acceleration are aware of their respective
responsibilities under the Securities Act of 1933 and the Securities
Exchange Act of 1934 as they relate to the proposed public offering
of the securities specified in the above registration statement. We
will act on the request and, pursuant to delegated authority, grant
acceleration of the effective date. We direct your attention to
Rules 460 and 461 regarding requesting acceleration of a registration
statement. Please allow adequate time after the filing of any
amendment for further review before submitting a request for
acceleration. Please provide this request at least two business days
in advance of the requested effective date.
Please direct all questions relating to the above comments to Jason
Wynn, at (202) 824-5665, or in his absence, to Jennifer Zatkowski, at
(202) 942-1911. Direct all correspondence to the following ZIP
code: 20549-0405.
Sincerely,
H. Roger Schwall
Assistant Director
cc: J. Wynn
J. Zatkowski
eFoodSafety.com, Inc.
September 9, 2004
page 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549-0405
DIVISION OF
CORPORATION FINANCE
eFoodSafety.com, Inc.
September 9, 2004
page 3
</TEXT>
</DOCUMENT>